Menu
Annual · values20252024202320222021202020192018
Operating Cash Flow-1.84 M USD-2.23 M USD-1.30 M USD544028 USD9161 USD552680 USD-217273 USD-274080 USD
Depreciation & Amortization111873 USD104160 USD83253 USD91427 USD91282 USD90787 USD41714 USD40611 USD
Stock-Based Compensation794770 USD141000 USD
Capital Expenditures36971 USD226989 USD18 USD54171 USD3162 USD421621 USD-12817 USD-39621 USD
Cash Flow from Investing944751 USD418202 USD-382576 USD-450498 USD-490574 USD1.32 M USD-12817 USD-51701 USD
Cash Flow from Financing298841 USD144975 USD5.75 M USD115962 USD-28222 USD-4947 USD-180805 USD742942 USD
Dividends Paid
Stock Buybacks
Free Cash Flow-1.88 M USD-2.46 M USD-1.30 M USD489857 USD5999 USD131059 USD-204456 USD-234459 USD

Bionexus Gene Lab Corp. operates as a biotechnology company with a focus on the research and development of genomic sequencing and analysis solutions. Its primary function is to advance personalized medicine by utilizing its genetic technologies to assist healthcare professionals in identifying and customizing treatment plans for patients based on their unique genetic profiles. Notable features of Bionexus Gene Lab Corp. include its cutting-edge laboratory facilities and a comprehensive database of genetic information, which enable it to provide accurate and efficient genomic testing services. The company plays a significant role in the healthcare and biopharmaceutical sectors, impacting areas such as precision oncology, hereditary disease prevention, and drug development. By facilitating a deeper understanding of genetic predispositions and responses, Bionexus Gene Lab Corp. is integral to the evolution of targeted therapies and personalized healthcare treatments, reflecting its importance in advancing modern medical practices.